GlassScriptPhysician profile
Benjamin P Sexton
NPI 1982905444
$2,649.72
in general payments reported to CMS, 2019-2025
29 companies · $479 in 2025
The $479 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $372 · 2022: $557 · 2023: $511 · 2024: $731 · 2025: $479.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,721.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,721.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $402.72 | 2021-2025 | |
| Pfizer INC. | $377.02 | 2021-2025 | |
| Novo Nordisk INC | $259.95 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $214.33 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Abbott Laboratories | $211.95 | 2021-2025 | Freestyle Libre, Freestyle Libre 3 |
| Amgen INC. | $162.22 | 2021-2025 | Repatha, Otezla, Repatha |
| Merck Sharp & Dohme LLC | $126.12 | 2021-2025 | Dificid, Gardasil 9, Capvaxive |
| Phathom Pharmaceuticals, INC. | $96.09 | 2023-2024 | Voquezna |
| Glaxosmithkline, LLC. | $92.41 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.63 | 2021-2025 | Jardiance |
| Corium, LLC | $56.27 | 2025 | Azstarys |
| Bayer Healthcare Pharmaceuticals INC. | $52.75 | 2022-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $51.88 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $51.53 | 2021-2025 | Farxiga, Airsupra |
| Dexcom, INC. | $51.13 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $48.39 | 2021-2024 | Veozah |
| Kowa Pharmaceuticals America, INC. | $44.04 | 2022-2024 | Zoryve |
| Collegium Pharmaceutical, INC. | $37.03 | 2025 | Jornay Pm |
| Sanofi Pasteur INC. | $36.19 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $32.00 | 2021-2022 | |
| Exact Sciences Corporation | $30.27 | 2023-2025 | Cologuard Collection Kit |
| Biohaven Pharmaceuticals, INC. | $28.29 | 2021 | |
| Currax Pharmaceuticals LLC | $25.94 | 2021-2022 | |
| Horizon Therapeutics Plc | $18.33 | 2021 | |
| Xeris Pharmaceuticals, INC. | $17.35 | 2023 | Gvoke Hypopen |
| Supernus Pharmaceuticals, INC. | $15.32 | 2022 | |
| Alfasigma USA, INC. | $13.33 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.28 | 2024 | Trulance, Xifaxan |
| Jazz Pharmaceuticals INC. | $11.96 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Sexton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.